On-Site Clinical/Translational Trials

Research Match, funded in part by the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program, is a quick and simplified way to search the studies available on ClincalTrials.gov. 

The following clinical/translational trials are active at the Boston-Providence clinical sites of the ILD Collaborative.

This is an MGH-based bioregistry to collect/store samples from patients with ILD for future research.
This translational study uses bronchoscopy to investigate how certain cells in the lung contribute to the development of pulmonary fibrosis.
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab as monotherapy in the absence of background IPF therapy or as combination therapy with pirfenidone background therapy in patients with idiopathic pulmonary fibrosis. Patients will be randomized to receive either lebrikizumab or placebo subcutaneously (SC) every 4 weeks.
The Pulmonary Fibrosis Foundation Patient Registry will collect data on at least 2,000 patients with interstitial lung disease (ILD) at approximately 40 clinical sites in the US. The Registry is targeting enrollment of approximately 60% of the 2,000 ILD participants to have idiopathic pulmonary fibrosis (IPF). The aim of the Registry is to create a cohort of well-characterized patients with interstitial lung disease (ILD) for participation in retrospective and prospective research.